
Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr.
- Bias Rating
- Reliability
90% ReliableExcellent
- Policy Leaning
10% Center
- Politician Portrayal
-6% Negative
Continue For Free
Create your free account to see the in-depth bias analytics and more.
By creating an account, you agree to our Terms and Privacy Policy, and subscribe to email updates.
Bias Score Analysis
The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.
Sentiments
7% Positive
- Liberal
- Conservative
Sentence | Sentiment | Bias |
---|---|---|
Unlock this feature by upgrading to the Pro plan. |
Reliability Score Analysis
Policy Leaning Analysis
Politician Portrayal Analysis
Bias Meter
Extremely
Liberal
Very
Liberal
Moderately
Liberal
Somewhat Liberal
Center
Somewhat Conservative
Moderately
Conservative
Very
Conservative
Extremely
Conservative
-100%
Liberal
100%
Conservative

Contributing sentiments towards policy:
59% : The Biden administration's proposal was crafted by the Centers for Medicare and Medicaid Services and is scheduled to be issued at 8:45 a.m. in the Federal Register.48% : " Becerra said the proposal would expand coverage of antiobesity drugs to 7.5 million people enrolled in Medicare and Medicaid, which his agency projected would add $25 billion in Medicare costs and $11 billion in Medicaid costs during the next decade.
48% : While the rules were written for the Medicare program, which covers older Americans, the new interpretation of weight-loss drugs also applies to Medicaid, which covers low-income Americans.
46% : The Biden administration Tuesday will propose expanding coverage of weight-loss medications for millions of Medicare and Medicaid beneficiaries, a late-term proposal that officials said would boost public health and which puts pressure on the incoming Trump administration to finalize the benefit.
46% : Under current rules, Medicare does not cover weight-loss medication, although many beneficiaries receive drugs such as Ozempic and Wegovy to treat diabetes and heart disease, conditions that can be exacerbated by obesity.
46% : The Congressional Budget Office, a nonpartisan agency, last month concluded that expanding coverage to antiobesity drugs would cost Medicare an additional $35 billion between 2026 and 2034 -- a figure higher than what the Biden administration estimates.
44% : Six in 10 adults believe that Medicare should cover the drugs for weight loss, with Democrats somewhat more likely than Republicans to be in favor, according to a poll released in May by KFF, a nonpartisan health-care research organization.
41% : Biden officials seeking to finalize their weight-loss proposal may find an ally in Mehmet Oz, the TV personality and cardiothoracic surgeon whom Trump last week tapped to lead CMS.
39% : Robert F. Kennedy Jr. -- whom Trump has selected to be the next HHS secretary, if confirmed by the Senate -- is an avowed critic of weight-loss drugs such as Ozempic, which he has blamed for obfuscating the root causes of poor health in America.
38% : The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.
38% : Becerra said the additional costs represented a modest fraction of the forecasted spending for Medicare, citing estimates that the program is expected to spend more than $2 trillion on drugs across the next decade.
*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.